Zimmer Biomet Holdings, Inc. research snapshot
ZBH AI stock analysis currently reads Zimmer Biomet as a mature medical technology company with stable orthopedic demand, improving 2026 execution, and a valuation that still depends heavily on adjusted EPS rather than GAAP earnings. At the August 2, 2026 data cutoff, ZBH closed near $93.93 on July 31, 2026, with a verified market cap near $18.17 billion. StockAnalysis reported 193.46 million shares outstanding, 24.36x trailing PE, 11.06x forward PE, 2.16x sales, 1.43x book value, and 15.95x free cash flow. The ZBH AI stock forecast remains scenario-based because upside depends on procedure volume, ROSA robotics and mBôs adoption, Paragon 28 and Monogram integration, debt reduction, pricing, tariffs, and whether investors accept non-GAAP earnings as the cleaner valuation base.
Current price
$93.93
Market cap
$18.17 billion verified market cap
AI score
63 / 100
Rating
Durable orthopedic implant incumbent with robotics and product-cycle optionality, but only moderate organic growth and a debt-heavy balance sheet
Trend status
Trading above the 50-day and 200-day averages after reclaiming them, with improving analyst sentiment
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Zimmer Biomet sells knee, hip, sports medicine, extremities, trauma, surgical, robotics, data, and related orthopedic technologies used by surgeons, hospitals, ambulatory surgery centers, and patients. | Medium-high |
| Moat | The moat comes from surgeon familiarity, clinical training, implant systems, hospital relationships, manufacturing quality, regulatory approvals, and installed procedure workflows, but switching costs are not as strong as software lock-in. | Medium |
| Management | Ivan Tornos has served as president and CEO since August 2023 and chairman since May 2025. Paul Stellato has served as interim CFO since April 2026. The current management test is whether product launches, robotics, acquisitions, restructuring, and buybacks can compound value without increasing execution risk. | High |
| Financial trend | FY2025 revenue rose 7.2% to $8.232 billion, while Q1 2026 revenue rose 9.3% to $2.087 billion and organic constant currency growth was 2.9%. TTM revenue reached $8.41 billion as of the March 2026 quarter. | High |
| Valuation | At the cutoff, StockAnalysis showed ZBH near 24.36x trailing earnings, 11.06x forward earnings, 2.16x sales, 1.43x book value, 15.95x free cash flow, and a PEG near 2.16, with a 27-analyst consensus Buy and an average price target near $99.38. | High |
| Technical trend | The stock closed near $93.93, above the 50-day moving average near $88.71 and the 200-day moving average near $91.11, with RSI near 56.32, making the trend improving after reclaiming both key averages. | Medium |
| Risk level | Risks include orthopedic procedure cyclicality, hospital pricing pressure, Stryker and J&J competition, product recalls, FDA oversight, ERP and supply chain disruption, acquisition integration, tariffs, interim CFO transition, and high debt. | Medium-high |
| AI confidence | Descriptive confidence is high because company filings, company releases, and StockAnalysis align on core numbers. Forward confidence is lower because adjusted EPS, procedure volume, and medtech sentiment drive the stock. | High data confidence |
| Investment certainty | ZBH may interest investors seeking a profitable medtech value setup, and the analyst consensus is Buy with a $99.38 average target, but the margin of safety depends on whether adjusted EPS guidance converts into cash flow while debt and integration risk decline. | Medium |
ZBH AI stock forecast
The ZBH AI stock forecast uses the $93.93 price reference, GAAP TTM EPS near $3.86, management updated 2026 adjusted diluted EPS guidance of $8.40 to $8.55, and a consensus 2026 adjusted EPS near $8.47. An adjusted EPS three-year model, using $8.47 as the starting point, produced a bearish area near $76, a base area near $114, and a bullish area near $151. The forecast range is wide because the market values ZBH on adjusted medtech earnings, but GAAP profitability, acquisition amortization, restructuring, debt, and integration costs still matter.
$125 to $150
More likely if 2026 revenue growth reaches the high end of the 2.5% to 4.5% guide, organic constant currency growth accelerates above 3%, adjusted EPS compounds from the $8.40 to $8.55 guide, robotics and new products lift mix, debt declines, the up to $1 billion buyback completes, and investors value ZBH near a mid-teens adjusted earnings multiple.
$100 to $120
More likely if procedure demand stays healthy, organic growth remains low single digit, adjusted EPS grows about 3% to 4% annually, free cash flow remains above $1 billion, and the market keeps ZBH near a low-to-mid-teens adjusted earnings multiple consistent with the consensus price target near $99.38.
$78 to $88
More likely if hip or knee growth slows, pricing pressure increases, Paragon 28 or Monogram integration absorbs more cash, debt reduction stalls, tariffs or ERP friction pressure margins, the interim CFO transition disrupts execution, or investors value ZBH closer to a single-digit adjusted earnings multiple.
ZBH AI technical analysis
ZBH AI technical analysis improved as of the August 2, 2026 cutoff. StockAnalysis showed a close near $93.93 on July 31, 2026, with the 50-day moving average near $88.71, the 200-day moving average near $91.11, RSI near 56.32, and average 20-day volume near 2.14 million shares. The stock has reclaimed both key averages, so the trend is improving, and a durable uptrend needs a hold above the 200-day area and a push toward the 52-week high near $108.29.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $93.93 | July 31, 2026 close used as the market-data reference for market-cap and valuation checks at the August 2, 2026 data cutoff. |
| Immediate support | $91 to $92 | This zone brackets the 200-day moving average reference near $91.11 and is the first test for the reclaimed uptrend. |
| Deeper support | $88 to $89 | This area brackets the 50-day moving average near $88.71. A decline into this zone would suggest the reclaim is losing sponsorship before the August 5, 2026 earnings date. |
| Near resistance | $95 to $99 | This area includes the analyst median target near $95 and the average price target near $99.38, and it is the first upside test after the recovery. |
| Major resistance | $103 to $108 | This zone approaches the 52-week high near $108.29. A breakout through it would signal a stronger recovery and a new uptrend leg. |
| Moving averages | 50-day near $88.71, 200-day near $91.11 | Price is above both the 50-day and 200-day averages, so trend quality has improved from the prior mixed setup. |
| Momentum | RSI near 56.32 | Momentum is positive but not overbought, which fits a stock that has reclaimed its averages but still needs earnings confirmation. |
| Volume | 20-day average near 2.14 million shares | A breakout above the $95 to $99 resistance zone is more credible if volume expands around the August 5, 2026 earnings date. |
| Volatility | Beta near 0.46 | StockAnalysis shows lower market beta, but earnings, guidance, regulatory, product, and integration news can still move the stock sharply. |
| Invalidation | Close below $91, then below $88.71 | A close below the 200-day area near $91 weakens the new uptrend. A break below the 50-day average near $88.71 would challenge the improving trend framework. |
ZBH AI trading strategy
The ZBH AI trading strategy below is a rules-based research framework, not personalized advice. It connects price behavior with orthopedic procedure demand, 2026 guidance, adjusted EPS, free cash flow, robotics milestones, integration progress, debt, buybacks, and competitive pressure.
Watch for ZBH to hold the $91 to $92 support area and then reclaim the $95 to $99 resistance zone while the August 5, 2026 results confirm procedure demand, adjusted EPS guidance, and free cash flow strength.
A failed reclaim followed by a close below $91 should reduce trend confidence, especially if guidance, organic growth, pricing, tariffs, or integration costs deteriorate.
If ZBH retests $88 to $89 without a material decline in procedure demand, free cash flow, or balance sheet quality, compare the lower price with the adjusted EPS base-case valuation.
Do not treat a lower price as automatically attractive if GAAP earnings weaken, debt rises, acquisition costs increase, or the market stops crediting adjusted EPS.
Track knee and hip growth, S.E.T. performance, Technology & Data growth, ROSA and mBôs robotics milestones, Paragon 28 integration, the interim CFO transition, adjusted operating margin, free cash flow, debt, and the up to $1 billion share repurchase program.
Position sizing should reflect that ZBH is a mature medtech execution story, not a guaranteed AI or robotics compounder.
Investment research summary
Customers pay Zimmer Biomet because orthopedic surgeons and hospitals need clinically trusted implants, instruments, robotics, data tools, and support systems that help restore mobility and standardize procedures.
The moat is strongest where surgeon training, implant compatibility, hospital contracts, clinical evidence, regulatory approvals, and procedure support create repeat use. It is weaker where rivals offer faster product cycles, stronger robotics ecosystems, or better pricing.
The thesis fails if low single-digit organic growth persists, Stryker and J&J take share, robotics investments do not convert into procedures, integration costs rise, debt limits flexibility, or GAAP earnings remain far below adjusted earnings.
Ivan Tornos has pushed product innovation, robotics, restructuring, acquisitions, and buybacks, including a $250 million buyback in Q1 2026 and a target of up to $1 billion for the year. The key management question is whether this mix improves durable growth without adding complexity faster than cash flow can absorb it, especially with an interim CFO in place.
Zimmer Biomet benefits from aging demographics, musculoskeletal procedure demand, outpatient orthopedic migration, robotics, surgical planning, AI-enabled navigation, and smart implant data. The offset is that the category is mature and pricing pressure remains persistent.
At $93.93, ZBH looks reasonably valued on forward adjusted EPS, with a consensus Buy and a $99.38 average price target, but less cheap on GAAP earnings and enterprise value. Margin of safety improves if free cash flow stays above $1 billion and debt falls, but weak organic growth would limit multiple expansion.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ZBH quote reference | $93.93 close on July 31, 2026 | StockAnalysis ZBH statistics | August 2, 2026 |
| Market capitalization verification | $18.17 billion reported and $18.17 billion calculated from $93.93 x 193.46 million shares, a 0.01% deviation | Pineify financial_rigor.py and StockAnalysis ZBH statistics | August 2, 2026 |
| Shares outstanding | 193.46 million shares outstanding, down 2.25% year over year | StockAnalysis ZBH statistics | August 2, 2026 |
| FY2025 revenue and net income | $8.232 billion revenue, $705.1 million GAAP net income, and $3.55 diluted EPS | Zimmer Biomet FY2025 earnings release and StockAnalysis financials | August 2, 2026 |
| Q1 2026 revenue and earnings | $2.087 billion net sales, $238.1 million GAAP net earnings, $1.22 GAAP diluted EPS, and $2.09 adjusted diluted EPS, with 2.9% organic constant currency growth | Zimmer Biomet Q1 2026 earnings release | August 2, 2026 |
| 2026 company guidance | Reported revenue change of 2.5% to 4.5%, organic constant currency growth of 1.0% to 3.0%, and updated adjusted diluted EPS of $8.40 to $8.55 | Zimmer Biomet Q1 2026 earnings release | August 2, 2026 |
| Cash, debt, and net debt | $424.2 million cash, $7.471 billion debt, and $7.047 billion net debt at March 31, 2026 | Zimmer Biomet Q1 2026 earnings release | August 2, 2026 |
| Valuation ratios | 24.36x trailing PE, 11.06x forward PE, 2.16x sales, 1.43x book value, 15.95x free cash flow, and PEG near 2.16 | StockAnalysis ZBH statistics | August 2, 2026 |
| Analyst consensus | Buy rating with a $99.38 average price target from 27 analysts, with a range of $83 to $130 | StockAnalysis ZBH forecast | July 28, 2026 |
| Technical references | 50-day moving average $88.71, 200-day moving average $91.11, RSI 56.32, and 20-day average volume 2.14 million shares | StockAnalysis ZBH statistics | August 2, 2026 |
| Leadership | Ivan Tornos is chairman, president, and CEO, with president and CEO appointment in August 2023 and chairman appointment in May 2025; Paul Stellato has served as interim CFO since April 2026 | Zimmer Biomet leadership page | August 2, 2026 |
This ZBH AI stock analysis is an informational research tool only and is not investment advice, a rating, or a guarantee of future performance. Forecast scenarios are based on publicly available data as of August 2, 2026 and can be wrong if earnings, guidance, procedure demand, competition, regulation, interest rates, debt, or market sentiment changes.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
